BeyondSpring Inc. said it was selling 739,095 common shares at $27.06 apiece in a registered offering with investors.
Gross proceeds from the transaction are expected to amount to $20 million.
The transaction will close May 31.
New York-based BeyondSpring is a clinical-stage company engaged in developing cancer therapies.
